NCT04957615View on ClinicalTrials.gov

Nivolumab for the Treatment of Metastatic or Unresectable Solid Tumors With ARID1A Mutation and CXCL13 Expression

PHASE2RecruitingINTERVENTIONAL

Enrollment

30

Participants

Timeline

Start Date

September 21, 2021

Primary Completion Date

May 31, 2027

Study Completion Date

May 31, 2027

Conditions

Metastatic Malignant Solid NeoplasmUnresectable Solid Neoplasm

Interventions

BIOLOGICAL

Nivolumab

Given IV

Trial Locations (1)

77030

RECRUITING

M D Anderson Cancer Center, Houston

All Listed Sponsors

lead

M.D. Anderson Cancer Center

OTHER